{
  "nctrialId": "HC-1710",
  "title": "A  Open-Label, Active-Controlled Multi-Center Study of MSC-135 (oligonucleotide) in Patients With Multiple Sclerosis",
  "officialTitle": "A  Open-Label, Active-Controlled Multi-Center Study of MSC-135 (oligonucleotide) in Patients With Multiple Sclerosis",
  "sponsor": "Centre for Addiction and Mental Health",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1710.json",
  "fileSize": 228907,
  "date": "2024-07-16",
  "completionDate": "2025-05-20",
  "drugName": "MSC-135 (oligonucleotide)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  open-label, active-controlled multi-center study designed to evaluate the efficacy and safety of MSC-135 (oligonucleotide) in patients with Multiple Sclerosis. The study will enroll approximately 333 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-71 years\n- Confirmed diagnosis of Multiple Sclerosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1710"
}